Pfizer to acquire Baxter's marketed vaccines

Pfizer Inc. (NYSE:PFE) will acquire the marketed vaccine portfolio of Baxter International Inc. (NYSE:BAX) for $635 million in cash. Baxter's marketed vaccines are NeisVac-C, a group C meningococcal polysaccharide conjugate vaccine; and FSME-IMMUN, also known as TicoVac, a tick-borne encephalitis vaccine. The vaccines are marketed in ex-U.S. territories, including the EU. Pfizer will also acquire a portion of Baxter's facility in Orth, Austria, where the vaccines are manufactured. ...